Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform

Area of Science:

• Medical Technology
• Patient Engagement
• Chronic Disease Management

Background:

• Cystic fibrosis (CF) is a complex, multi-system disease requiring intensive daily treatment.
• Sub-optimal adherence to CF therapies significantly impacts clinical and economic burden.
• Cystic Fibrosis Transmembrane Conductance Regulator modulators (CFTRm) are high-cost, effective medications for CF.

Purpose of the Study:

• To evaluate the safety, usability, and efficacy of the ReX platform for medication management of CFTR modulators in people with CF (pwCF).

Main Methods:

• Prospective, multi-center, open study involving pwCF (age > 12) prescribed CFTRm (ETI or TI).
• ReX platform used for medication dispensing, reminders, and adherence data collection.
• Study duration 12-24 months, including clinical visits with physical exams, BMI, pulmonary function tests, and user experience questionnaires.

Main Results:

• Median adherence to CFTRm was 97.5% (year 1) and 94% (year 2), exceeding the reported ~80% adherence.
• No adverse events related to the ReX platform were reported; patients found it valuable and user-friendly.
• Significant improvements observed: mean FEV1% increased from 74.4% to 80.8% (p=0.004), and BMI percentile increased from 53.5 to 59.0 (p<0.001).

Conclusions:

• The ReX platform is a safe, user-friendly, and effective tool for managing CFTRm in pwCF.
• The platform demonstrates potential to improve treatment adherence and clinical outcomes.
• Further large-scale, long-term studies are warranted to confirm clinical benefits and cost-effectiveness.